Publications

Butt T, Liu GG, Kim DD, Neumann PJ. Taking stock of cost-effectiveness analysis of healthcare in China. BMJ Global Health 2019;4(3):1–9. 31179038

Chambers JD, Panzer AD, Kim DD, Margaretos NM, Neumann PJ. Variation in US private health plans’ coverage of orphan drugs. The American Journal of Managed Care. 2019;25(10):508-512. 31622066

Chambers JD, Panzer AD, Pope EF, Graff JS, Neumann PJ. Little consistency in evidence cited by commercial plans for specialty drug coverage. Health Affairs 2019;38(11):1882–6. 31682500

Cohen JT, Silver MC, Ollendorf DA, Neumann PJ. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments? Value in Health 2019;22(12):1396–401. 31806196

Drummond MF, Neumann PJ, Sullivan SD, Fricke FU, Tunis S, Dabbous O, Toumi M. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value in Health 2019 (in press). 31198183

Emerson J, Bacon R, Kent A, Neumann PJ, Cohen JT. Publication of decision model source code: Attitudes of health economics authors. PharmacoEconomics 2019;:1–2. 31214898

Emerson J, Panzer A, Cohen JT, Chalkidou K, Teerawattananon Y, Sculpher M, Wilkinson T, Walker D, Neumann PJ, Kim DD. (2019) Adherence to the iDSI reference case among published cost-per-DALY averted studies. PLoS ONE 14(5): e0205633. 31042714

Garrison LP, Neumann PJ, Willke RJ. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy. Journal of Managed Care & Specialty Pharmacy 2019;25(11):1185–92. 31663458

Herman PM, Broten N, Lavelle TA, Sorbero ME, Coulter ID. Exploring the prevalence and construct validity of high-impact chronic pain across chronic low-back pain study samples. The Spine Journal 2019 (in press). 30885677

Herman PM, Broten N, Lavelle TA, Sorbero ME, Coulter ID. Healthcare Costs and Opioid Use Associated with High-Impact Chronic Spinal Pain in the United States. Spine 2019 (in press). 31373999

Hlávka JP, Lin PJ, Neumann PJ. Outcome measures for oncology alternative payment models: Practical considerations and recommendations. The American Journal of Managed Care 2019. 31860235

Kim DD, Cohen JT, Wong JB, Mohit B, Fendrick AM, Kent DM. Targeted incentive programs for lung cancer screening can improve population health and economic efficiency. Health Affairs 2019;38(1):60–7. 30615528

Kim DD, Guzauskas GF, Bennette CS, Basu A, Veenstra DL, Ramsey SD, Carlson JJ. Influence of modeling choices on value of information analysis: An empirical analysis from a real-world experiment. PharmacoEconomics 2019;:1–9. 31631254

Kim DD, Neumann PJ. "Comparative modeling to inform health policy decisions: A step forward," Annals of Internal Medicine Editorial," November 4, 2019. 31683277

Kim DD, Trikalinos TA, Wong JB. Leveraging cumulative network meta-analysis and value of information analysis to understand the evolving value of medical research. Medical Decision Making 2019;39(2):119–29. 30678537

Kim DD, Wilde PE, Michaud DS, Liu J, Lizewski L, Onopa J, Mozaffarian D, Zhang FF, Wong JB. Cost Effectiveness of Nutrition Policies on Processed Meat: Implications for Cancer Burden in the U.S. American Journal of Preventive Medicine 2019;57(5). 31564600

Lavelle TA, Messonnier M, Stokley S, et al. Use of a choice survey to identify adult, adolescent and parent preferences for vaccination in the United States. Journal of Patient-Reported Outcomes 2019;3(1). 31359289

Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, Prosser LA. Parent preferences for health outcomes associated with autism spectrum disorders. PharmacoEconomics 2019;37(4):541–51. 30895565

Lin PJ, D'Cruz B, Leech AA, Neumann PJ, Aigbogun MS, Oberdhan D, Lavelle TA. Family and caregiver spillover Effects in cost‑utility analyses of alzheimer’s disease interventions. PharmacoEconomics 2019;37(3):1–12. 30903567

Neumann PJ. Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime Time. Value in Health 2019;22(9):975–6. 31511185

Wright DR, Saelens BE, Fontes A, Lavelle TA. Assessment of Parents’ Preferences for Incentives to Promote Engagement in Family-Based Childhood Obesity Treatment. JAMA Network Open 2019;2(3). 30924902

Chambers J, Pope E, Bungay K, Cohen JT, Ciarametaro M, Dubois R, Neumann PJ. A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. Value in Health 2018;21(4):400–6. 29680096

Chambers JD, Kim DD, Pope EF, Graff JS, Wilkinson CL, Neumann PJ. Specialty Drug Coverage Varies Across Commercial Health Plans In The US. Health Affairs 2018;37(7):1041–7. 29985695

Chambers JD, Pope EF, Wilkinson CL, Neumann PJ. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies. Journal of Managed Care & Specialty Pharmacy 2018;24(12):1240–6. 30479201

Garrison LP, Neumann PJ, Willke RJ, et al. A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health 2018;21(2):161–5. 29477394

Garrison LP, Pauly MV, Willke RJ, Neumann PJ. An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2]. Value in Health 2018;21(2):124–30. 29477389

Goldman DP, Fillit H, Neumann P. Accelerating Alzheimers disease drug innovations from the research pipeline to patients. Alzheimers & Dementia 2018; 29680407

Kim DD, Arterburn DE, Sullivan SD, Basu A. Economic Value of Greater Access to Bariatric Procedures for Patients With Severe Obesity and Diabetes. Medical Care 2018;:1. 29762271

Kumar V, Cohen JT, Klaveren DV, Soeteman DI, Wong JB, Neumann PJ, Kent DM. Risk-Targeted Lung Cancer Screening. Annals of Internal Medicine 2018;168(3):161. 30083710

Ladin K, Emerson J, Berry K, Butt Z, Gordon EJ, Daniels N, Lavelle TA, Hanto DW. Excluding patients from transplant due to social support: Results from a national survey of transplant providers. American Journal of Transplantation 2018; 29878515

Lavelle TA, D’Cruz BN, Mohit B, Ungar WJ, Prosser LA, Tsiplova K, Monserrat VL, Lin PJ. Family spillover effects in pediatric cost-utility analyses. Applied Health Economics and Health Policy 2018; 30350218

Lavelle TA, Kent DM, Lundquist CM, Thorat T, Cohen JT, Wong JB, Olchanski N, Neumann PJ. Patient Variability Seldom Assessed in Cost-Effectiveness Studies. Medical Decision Making 2018; 29351053

Lavelle TA, Rose AJ, Timbie JW, Setodji CM, Wensky SG, Giuriceo KD, Friedberg MW, Malsberger R, Kahn KL. Utilization of health care services among Medicare beneficiaries who visit federally qualified health centers. BMC Health Services Research 2018;18(1). 29370837

Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value in Health 2018;21(7):759–61. 30005746

Lin P-J, Pope E, Zhou FL. Comorbidity Type and Health Care Costs in Type 2 Diabetes: A Retrospective Claims Database Analysis. Diabetes Therapy 2018; 30097994

Melnitchouk N, Soeteman DI, Davids, JS, Fields A, Cohen JT, Noubary F, Lukashenko A, Kolesnik OO, Freund KM. Colorectal cancer screening cost saving in Ukraine. PharmacoEconomics & Outcomes News 2018;805(1):11–. 29977160

Neumann PJ, Anderson JE, Panzer AD, Pope EF, D'Cruz BN, Kim DD, Cohen JT. Comparing the cost-per-QALYs gained and cost-per-DALYs averted literatures. Gates Open Research 2018;2:5. 29431169

Neumann PJ, Cohen JT. QALYs in 2018—Advantages and Concerns. Jama 2018;319(24):2473. 29800152

Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, Owens DK, Meltzer DO, Kuntz KM, Krahn M, Feeny D, Basu A, Russell LB, Siegel JE, Ganiats TG, Sanders GD. Future Directions for Cost-effectiveness Analyses in Health and Medicine. Medical Decision Making 2018;38:767-77. 30248277

Neumann PJ, Willke RJ, Garrison LP. A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1]. Value in Health 2018;21(2):119–23. 29477388

Olchanski N, Hansen RN, Pope E, Fergie J, Goldstein M, Krilov LR, McLaurin KK, Nabrit-Stephens B, Oster G, Schaecher K, Shaya FT, Neumann PJ, Sullivan SD. Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value. Open Forum Infectious Diseases 2018;5(3). 29516023

Olchanski N, Vest A, Rane P, Neumann PJ, DeNofrio D. Cost Comparison Across Heart Failure Patients With Reduced And Preserved Ejection Fractions: Analyses Of Inpatient Decompensated Heart Failure Admissions. Journal of the American College of Cardiology 2016;67(13):1469. 29657034

Parsons SK, Kelly MJ, Cohen JT, Castellino SM, Henderson TO8, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, Evens AM. Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. British Journal of Haematology 2018;182(2):212–21. 29707774

Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science 2018;360(6386):278–9. 29674586

Thokala P, Ochalek J, Leech AA, Tong T. Cost-Effectiveness Thresholds: the Past, the Present and the Future. PharmacoEconomics 2018;36(5):509–22. 29427072

Thorat T, Neumann PJ, Chambers JD. Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia. Journal of Managed Care & Specialty Pharmacy 2018;24(7):632–42. 29952709

Willke RJ, Neumann PJ, Garrison LP, Ramsey SD. Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report [6]. Value in Health 2018;21(2):155–60. 29477393

Bilinski A, Neumann P, Cohen J, Thorat T, Mcdaniel K, Salomon JA. When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. PLOS Medicine 2017;14(10). PMID: 28968399

Chambers JD, Anderson JE, Salem MN, Bugel SG, Fenech M, Mason JB, Weber P, West KP, Wilde P, Booth SL. The decline in vitamin research funding: a missed opportunity? Current Developments in Nutrition 2017;1(8). PMID: 29955714

Chambers JD, Thorat T, Wilkinson CL, Neumann PJ. Drugs cleared through the FDA’s expedited review offer greater gains than drugs approved by conventional process Health Affairs 2017;36(8):1408–15. PMID: 28784733 

Chambers JD, Saret CJ, Anderson JE, Deverka PA, Douglas MP, Phillips KA. Examining evidence in U.S. payer coverage policies for multi-gene panels and sequencing tests. International Journal of Technology Assessment in Health Care 2017;:1–7. PMID: 29065945

Chambers JD, Salem MN, D’Cruz BN, Subedi P, Kamal-Bahl SJ, Neumann PJ. A review of empirical analyses of disinvestment initiatives. Value in Health 2017;20(7):909–18. PMID: 28712620 

Chambers JD, Anderson JE, Wilkinson CL, Pallavi R. Variation in the coverage of disease-modifying multiple sclerosis drugs among US payers. Am J Pharm Benefits. 2017;9(5):155-159.

Cohen JT, Neumann PJ, Wong JB. A call for open-source cost-effectiveness analysis. Annals of Internal Medicine 2017;167(6):432. PMID: 29610903

Cohen JT, Wong JB. Can economic model transparency improve provider interpretation of cost-effectiveness analysis? A response. Medical Care 2017;55(11):912–4. PMID: 29028754

Cohen JT, Anderson JE, Neumann PJ. Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. Value in Health 2017;20(2):193–9. PMID: 28237194 

Kim DD, Arterburn DE, Sullivan SD, Basu A. Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery. Obesity Surgery 2017. PMID: 29086183 

Kim DD, Wilkinson CL, Pope EF, Chambers JD, Cohen JT, Neumann PJ. The influence of time horizon on results of cost-effectiveness analyses. Expert Review of Pharmacoeconomics & Outcomes Research 2017;17(6):615–23. PMID: 28504026 

Kim DD, Basu A. New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives. Medical Decision Making 2017;37(8):930–41. PMID: 28441507

Lin P-J, Zhong Y, Fillit HM, Cohen JT, Neumann PJ. Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among medicare beneficiaries with Alzheimer's disease. Alzheimers & Dementia 2017;13(10):1174–8. PMID: 28886338

Jönsson L, Lin P-J, Khachaturian AS. Special topic section on health economics and public policy of Alzheimers disease. Alzheimers & Dementia 2017;13(3):201–4. PMID: 28232007 

Lin P-J, Yeh W-S, Neumann PJ. Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy. Pediatric Neurology 2017;66:69–75. PMID: 27769729 

Neumann PJ, Sanders GD. Cost-Effectiveness Analysis 2.0. N Engl J Med. 2017 Jan 19;376(3):203-205. PMID: 28099837 

Neumann, PJ, Pope E. “Cures Act, FDA Draft Guidance Suggest Flexibility On Communication Of Real-World Drug Impacts, Though Questions Remain, " Health Affairs Blog, February 2, 2017.

Neumann PJ, Cohen JT. ICER’s  revised value assessment framework for 2017–2019: A critique. PharmacoEconomics 2017;35(10):977–80. PMID: 28791663 

Neumann PJ, Thorat T, Zhong Y, Anderson JE, Farquhar M, Salem MN, Sandberg E, Saret CJ, Wilkinson CL, Cohen JT. A systematic review of cost-effectiveness studies reporting cost-per-DALY averted. Plos One 2016;11(12). PMID: 28005986 

Olchanski N, Cohen JT, Neumann PJ, Wong JB, Kent DM. Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. Medical Decision Making 2017;37(7):790–801. PMID: 28399375 

Chambers JD, Chenoweth MD, Pyo J, Cangelosi MJ, Neumann PJ. Changing face of Medicare’s National Coverage Determinations for technology. Int J Technol Assess Health Care. 2015 Jan;31(5):347-54. PMID: 26750558 

Chambers JD, Rane PB, Neumann PJ. The impact of formulary drug exclusion policies on patients and healthcare costs. Am J Manag Care. 2016 Aug;22(8):524-31. PMID: 27541699 

Chambers JD, Chenoweth MD, Neumann PJ. Mapping US commercial payers’ coverage policies for medical technology. Am J Manag Care. 2016 Sep 1;22(9):e323-8. PMID: 27662396 

Chambers JD, Thorat T, Wilkinson CL, Salem M, Subedi P, Kamal-Bahl SJ, Neumann PJ. Estimating population health benefits associated with specialty and traditional drugs in the year following product approval. Appl Health Econ Health Policy. 2017 Apr;15(2):227-235. PMID: 27832480 

Chambers JD, Wilkinson CL, Anderson JE, Chenoweth MD. Variation in private payer coverage of rheumatoid arthritis drugs. J Manag Care Spec Pharm. 2016;22(10):1176-81. PMID: 27668566

John-Baptiste A, Schapira MM, Cravens C, Chambers JD, Neumann PJ, Siegel JE, Lawrence W. The role of decision models in health care policy. Med Decis Making July 2016 vol. 36 no. 5 666-679. PMID: 27225487 

Leopold C, Chambers JD, Wagner AK. Thirty years of media coverage on high drug prices in the United States-A never-ending story or a time for change? Value Health. 2016 Jan;19(1):14-6. PMID: 26797230 

Lin PJ, Saret CJ, Neumann PJ, Sandberg EA, Cohen JT. Assessing the value of treatment to address various symptoms associated with multiple sclerosis: Results from a contingent valuation study. Pharmacoeconomics. 2016 Jul 26. PMID: 27461538 

Lin PJ, Winn AN, Parsons SK, Neumann PJ, Weiss ES, Cohen JT. Linking costs and survival in the treatment of older adults with chronic myeloid leukemia: An analysis of SEER-Medicare data from 1995 to 2007. Medical Care. 2016 Apr;54(4):380–385. PMID: 26759984 

Lin PJ, Yeh WS, Neumann PJ. Willingness to pay for a newborn screening test for spinal muscular atrophy. Pediatric Neurology. 2016. PMID: 27769729 

Lin PJ, Zhong Y, Fillit HM, Chen E, Neumann PJ. Medicare expenditures of individuals with Alzheimer’s disease and related dementias. J Am Geriatr Soc. 2016 Aug;64(8):1549-57. PMID: 27295430

Neumann PJ, Farquhar M, Wilkinson CL, Lowry M, Gold M. Lack of cost-effectiveness analyses to address healthy people 2020 priority areas. Am J Public Health. 2016 Sep 15:e1-e3. PMID: 27631752 

Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-effectiveness in health and medicine- 2nd Ed. Oxford Univ Press. 2016. 

Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA; Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG,  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016; 316(10):1093-103. PMID: 27623463

Simon-Tuval T, Neumann PJ, Greenberg D. Cost-effectiveness of adherence-enhancing interventions: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016 Feb;16(1):67-84. PMID: 26732615 

Zhong Y, Cohen JT, Goates S, Luo M, Nelson J, Neumann PJ. The cost-effectiveness of oral nutrition supplementation for malnourished older hospital patients. Appl Health Econ Health Policy. 2016 Aug 4. PMID: 27492419 

Chambers, JD, Cangelosi, MJ, Neumann, PJ. Medicare’s use of cost-effectiveness analysis for prevention (but not for treatment). Health Policy 2015 Feb (119)2:156-163. PMID: 25498476 

Chambers, JD, Chenoweth M, Cangelosi MJ, Pyo J, Cohen JT, Neumann PJ. Medicare is Scrutinizing Evidence More Tightly for National Coverage Determinations. Health Affairs 2015; 34(2):253–260. PMID: 25646105 

Chambers JD, Chenoweth M, Thorat T, Neumann, PJ. Private Payers Disagree With Medicare Over Medical Device Coverage About Half The Time. Health Aff August 2015 vol. 34 no. 8 1376-1382. PMID: 26240252 

Chambers JD, Naci H, Wouters OJ, Pyo J, Gunjal S, Kennedy IR, Hoey MG, Winn A, Neumann PJ. An assessment of the methodological quality of published network meta-analyses: A systematic review. PLOS ONE 29 April 2015. PMID: 26196938 

Chambers JD, Thorat T, Pyo J, Neumann PJ. The Lag from FDA Approval to Published Cost-Utility Evidence. Expert Rev Pharmacoecon Outcomes Res. 2015 Jan 12:1-4. PMID: 25579324 

Lin P-J, Kent DM, Winn A, Cohen JT, Neumann PJ. Multiple Chronic Conditions in Type 2 Diabetes Mellitus: Prevalence and Consequences. AJMC 2015;21(1):e23-e34. PMID: 25880265 

Neumann PJ, Cohen JT. Measuring the Value of Prescription Drugs. NEJM Perspective. 2015. PMID: PMID: 26580666 

Neumann PJ, Saret C. When Does FDAMA Section 114 Apply? Ten Case Studies. Value in Health July 2015 (18) 5: 682-689. PMID: 26297097 

Neumann PJ, Thorat T, Shi J, Saret CJ, Cohen JT. The Changing Face of the Cost Utility Literature, 1990-2012. Value in Health 2015. 18(2):271-277. PMID: 25773562 

Olchanski N, Zhong Y, Cohen JT, Saret C, Bala M, Neumann PJ. The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology. Expert Rev Pharmacoecon Outcomes Res. 2015 Oct 19:1-10. PMID: 26478989 

Saret CJ, Winn A, Shah G, Parsons SK, Lin PJ, Cohen JT, Neumann PJ. Value of Innovation in Hematologic Malignancies: A Systematic Review of Published Cost-Effectiveness Analyses. Blood 2015 First Edition. PMID: 25655601 

Thorat T, Lin PJ, Neumann PJ. The State of Cost-Utility Analyses in Asia: A Systematic Review. Value Health Regional Issues. 2015 May 7–13. PMID: 29698196 

Winn AN, Shah GL, Cohen JT, Lin PJ, Parsons SK. The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. J Natl Cancer Inst. 2015 May 28;107(8). PMID: 26023094 

Zhong Y, Lin P-J, Cohen JT, Winn A, Neumann PJ. Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence. Value in Health 2015;18(2):308-314. PMID: 25773567 

Chambers JD. Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA? Pharmacoeconomics. 2014 Aug;32(8):729-33. PMID:  24859242 

Chambers JD, Cangelosi MJ, Neumann PJ. Medicare's use of cost-effectiveness analysis for prevention (but not for treatment). Health Policy. 2014 Nov 22.  PMID: 25498476

Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Affairs (Millwood). 2014 Oct;33(10):1751-60. PMID: 25288419 

Chambers JD, Winn A, Zhong Y, Olchanski N, Cangelosi MJ. Potential role of network meta-analysis in value-based insurance design. The American Journal of Managed Care. 2014 Aug;20(8):641-8. PMID: 25295678 

Cohen, JT. FDA’s proposed ban on trans fats: how do the costs and benefits stack up? Clinical Therapeutics. 2014 Jan; 36(3): 322-327. PMID: 24636817 

Hallikainen I, Martikainen J, Lin PJ, Cohen JT, Lahoz R, Valimaki T, Hongisto K, Vaatainen S, Vanhansen M, Neumann PJ, Hanninen T, Koivisto AM. The Progression of Alzheimer’s Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study. Dementia and Geriatric Cognitive Disorders Extra. 2014; 4(1): 494-508. Published online 11 Dec 2014. PMID: 25685140 

Husereau D, Culyer AJ, Neumann PJ, Jacobs P. How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States? Appl Health Econ Health Policy. 2014; Published online 15 October 2014. PMID: 25316309 

Lin PJ, Yang Z, Fillit HM, Cohen JT, Neumann PJ. Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease. Health Affairs (Millwood). 2014 Apr;33(4):547-54. PMID: 24711313 

Neumann PJ, Saret CJ. Is the US "leading from behind" on health policy? European Journal of Health Economics. 2014 Mar;15(2):113-6. PMID: 24323196 

Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. New England Journal of Medicine. 2014 Aug 28;371(9):796-7. PMID: 25162885 

Olchanski N, Winn A, Cohen JT, Neumann PJ. Abdominal aortic aneurysm screening: how many life years lost from underuse of the medicare screening benefit? J Gen Intern Med. 2014 Aug;29(8):1155-61. PMID: 24715406 

Zalesak M, Greenbaum JS, Cohen JT, Kokkotos F, Lustig A,Neumann PJ, Pritchard D, Stewart J, Dubois RW. The value of specialty pharmaceuticals - a systematic review. American Journal Managed Care. 2014 Jun;20(6):461-72. PMID: 25180434 

Chambers JC, Weiner DE, Bliss SK, Neumann PJ. What can we learn from the US expanded end-stage renal disease bundle? Health Policy. 2013; (110):164-171. PMID: 23419419

Lerner D, Rodday AM, Cohen JT, Rogers WH. A Systematic Review of the Evidence Concerning the Economic Impact of Employee-Focused Health Promotion and Wellness Programs. J Occup Environ Med. 2013 Jan 2. [Epub ahead of print] PMID: 23287723

Lin PJ, Neumann PJ. The economics of mild cognitive impairment. Alzheimers and Dementia. 2013; (9):58–62. PMID: 23141385

Lin PJ, Fillit HM, Cohen JT, Neumann PJ. Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer’s disease and related disorders. Alzheimer’s & Dementia 9 (2013) 30–38. PMID: 23305822

Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The Validity of Dependence as a Health Outcome Measure in Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2013 Mar 19. [Epub ahead of print] PMID: 23512996

Barshes NR, Chambers JD, Cohen JT, Belkin M. Cost Effectiveness in the contemporary management of critical limb ischemia with tissue loss. Journal of Vascular Surgery. 2012 Oct;56(4):1015-1024.PMID: 22854267

Barshes NR, Chambers JD, Cantor SB, Cohen J, Belkin M. A primer on cost-effectiveness analyses for vascular surgeons. Journal of Vascular Surgery. 2012 Jun;55(6):1794-800.PMID: 22608043

Cangelosi MJ, Bliss SK, Chang H, Dubois RW, Lerner D, Neumann PJ, Westrich K, Cohen JT. Imputing productivity gains from clinical trials. Journal of Occupational and Environmental Medicine.2012 Jul;54(7):826-33.PMID: 22796927

†Chambers JD, Morris S, Neumann PJ, Buxton MJ. Factors Predicting Medicare National Coverage. Medical Care. 2012 Mar;50(3):249-56.PMID: 22193418

Cohen JT, Marino RJ, Sacco P, Terrin N. Association between the Functional Independence Measure following spinal cord injury and long term outcomes. Spinal Cord. 2012 Oct;50(10):728-33.PMID: 22641254

Cohen JT, Miller G, Roehrig C. Cost-Effectiveness of Cardiovascular Disease Spending. Journal of the American College of Cardiology. 2012;60(20):2123-2124.PMID: 22193418

Doshi JA, Hodgkins P, Kahle J, Sikirika V, Cangelosi MJ, Setyawan J, Erder MH, Neumann PJ. Economic Impact of Childhood and Adult Attention-Deficit. Hyperactivity Disorder in the United States. Journal of the American Academy of Child & Adolescent Psychiatry. 2012 October; 51(10): 990-1002.PMID: 23021476

Drummond M, Neumann PJ, Jonsson B, Luce B, Schwartz JS, Siebert U, Sullivan SD. Can we reliably benchmark health technology assessment organizations? International Journal of Technology Assessment in Health Care. 28:2(2012):159-165.PMID: 22559758

Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, Pietzsch JB. Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension. Journal of the American College of Cardiology 2012; 60(14):1271-7.PMID: 22981547

Gray GM, Cohen JT. Rethink Chemical Risk Assessments. Nature. 2012 Sep 6;489(7414):27-8.PMID: 22955594

Hammerman A, Feder-Bubis P, Greenberg D. Financial risk-sharing in updating the national list of health services in Israel: stakeholders' perceived interests. Value in Health. 2012 Jul-Aug;15(5):737-42.PMID: 22867784

Leslie LK, Cohen JT, Newburger JW, Alexander ME, Wong JB, Sherwin ED, Rodday AM, Parsons SK, Triedman JK. Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. Circulation. 2012 May 29;125(21):2621-9.PMID: 22556340

Luce BR, Drummond MF, Dubois RW, et al. Principles for planning and conducting comparative effectiveness research. Journal of Comparative Effectiveness Research. 2012; 1(5): 431-440.

Lin PJ, Neumann PJ. The economics of mild cognitive impairment. Alzheimers and Dementia. 2012;1-5.PMID: 23141385

Neumann PJ, Bliss SK. FDA actions against health economic promotions, 2002-2011. Value in Health.2012 Sep;15(6):948-53.PMID: 22999146

Neumann PJ, Bliss SK, Chambers JD. Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries. Health Affairs. 2012 Apr;31(4):700-8.PMID: 22492886

Neumann PJ, Chambers JD. Medicare's enduring struggle to define 'reasonable and necessary' care. New England Journal of Medicine. 2012 October 31.367(19):1775-1777.

Neumann PJ, What we talk about when we talk about health care costs. New England Journal of Medicine. 2012 Feb;366(7):585-86.PMID: 22335735

Neumann, PJ, Cohen, JT, Hammitt, JK, Concannon, TW, Auerbach, HR, Fang, CH, Kent, DM. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Economics. 2012 Mar;21(3):238-51.PMID: 22271512

O’Grady MJ, John P, Winn A. Substantial Medicare savings may result if insurers cover ‘artificial pancreas’ sooner for diabetes patients. Health Affairs. 2012 Aug;31(8):1822-9.PMID: 22869661

Otero HJ, Chambers JD, Bresnahan BW, Kamae MS, Yucel KE, Neumann PJ. Medicare's National Coverage Determinations in Diagnostic Radiology: Examining Evidence and Setting Limits. Academic Radiology. 2012 Sep;19(9):1060-5.PMID: 22748382

Rodday AM, Triedman JK, Alexander ME, Cohen JT, Ip S, Newburger JW, Parsons SK, Trikalinos TA, Wong JB, Leslie LK. Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic Children: A meta-analysis. Pediatrics. 2012 Apr;129(4):e999-1010.PMID: 22392183

*Thorat T, Cangelosi M, Neumann PJ. Skills of the trade: The Tufts cost-effectiveness analysis registry. Journal of Benefit-Cost Analysis. 2012 Feb;3(1):1-7.

Wilson AW, Neumann PJ, The cost-effectiveness of biopharmaceuticals: A look at the evidence. MAbs. 2012 Mar 1;4(2).PMID: 22377753

* Publication used data from CEA Registry
† Publication used data from NCD database

Buxton, MJ, Chambers, JD. What values do the public want their health care systems to use in evaluating technologies? European Journal of Health Economics. Published online May 15, 2011. PMID: 21573933

Cangelosi, MJ, Auerbach, HR, Cohen, JT. A clinical and economic evaluation of enteral nutrition. Current Medical Research Opinion. 2011 Feb;27(2):413-22. Epub 2010 Dec 30. PMID: 21192760

†Chambers JD, Morris S, Neumann PJ, Buxton M. Factors predicting Medicare national coverage: An empirical analysis. Medical Care. 2011 Dec 28. PMID: 22193418

Chambers J, Neumann PJ. Listening to Provenge — what a costly cancer treatment says about Medicare policy on new technology. New England Journal of Medicine. 2011 May 5;364(18):1687-9. PMID: 21470004

Gazelle GS, Kessler L, Lee DW, McGinn T, Menzin J, Neumann PJ, van Amerongen D, White LA. The Working Group on Comparative Effectiveness Research for Imaging. A framework for assessing the value of diagnostic imaging in the era of comparative effectiveness research. Radiology 2011 Dec;261(3):692-698. PMID: 22095993

*Greenberg, D., Neumann, PJ. Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions? Expert Reviews 2011. Published online 2011. PMID: 21351863

*Kamae MS, Kamae I, Cohen JT, Neumann PJ. Regression analysis on the variation in efficiency frontiers for prevention stage of HIV/AIDS. Journal of Medical Economics 2011. Published online 2011. PMID: 21332273

Maciejewski ML, Wang VW, Grabowski DC, Lin PJ. Early evidence on the quality of care provided by special needs plans. Medical Care 2011;49(10):891-896. PMID: 21572358

Neumann PJ, Chambers J, Simon F, Meckley L. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Affairs. 2011 Dec; 30(4): 2329-2337. PMID:22147861

Neumann, PJ, Cohen, JT, Hammitt, JK, Concannon, TW, Auerbach, HR, Fang, CH, Kent, DM. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Economics 2011. Published online Dec. 28, 2010. PMID: 21190163

Neumann PJ. What’s next for QALYs. Journal of the American Medical Association 2011 May; 305(17):1806-1807. PMID: 21540426

Neumann PJ, Lin PJ, Hughes TE. FDAMA Section 114: Current Uses and Opportunities for Comparative Effectiveness Research. Pharmacoeconomics 2011 July; 29(8):687-692. PMID: 21540426

Yang Z, Zhang K, Lin PJ, Clevenger CK, Atherly A. A longitudinal analysis of the lifetime cost of dementia. Health Services Research. 2011 Dec 15. PMID: 22171532.

 * Publication used data from CEA Registry
 † Publication used data from NCD database

Brixner, DI, Holtorf, AP, Neumann, PJ, Malone, DC, Watkins, JB Standardizing quality assessment of observational studies for decision making in health care. J Manag Care Pharm. 2009;15:(3)275-283. PubMed: 19326959

Berry SR, Bell CM, Ubel PA et al. Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated with New Cancer Drugs. J Clin Oncol 2010 PubMed: 20697077

Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010; 96:179-190.

†Chambers JD, Neumann PJ, Buxton MJ. Does Medicare Have an Implicit Cost-Effectiveness Threshold? Medical Decision Making 2010. PubMed: 20551473

Chambers JD, Neumann PJ. US healthcare reform: implications for health economics and outcomes research. Expert Review Pharmacoeconomic Outcomes Research 2010; 10(3):215-216. PubMed: 20545583

Cohen JT, Neumann PJ. Using decision analysis to better evaluate pediatric clinical guidelines. Health Affairs. 2008 Sep-Oct;27(5):1467-75. PubMed: 18780939

Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. New England Journal of Medicine. 2008 Feb(7);358:661-663. PubMed: 18272889

Cohen JT. Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis. Expert Review Pharmacoeconomic Outcomes Research 2010; 10(5):595-603. PubMed

Fillit H, Cummings J, Neumann PJ, McLaughin T. Salvatore P, Leibman C. Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer’s disease. The Journal of Nutrition Health & Aging 2010; 14(8):640-647.c

Freeman RB, Cohen JT. Transplantation risks and the real world: what does 'high risk' really mean? Am J Transplant 2009; 9(1):23-30. PubMed: 19067660

Gabbay E, Calvo-Broce J, Meyer KB, Trikalinos TA, Cohen J, Kent DM. The empirical basics for determinations of medical futility. General Internal Medicine 2010; 25(10):1083-10839.

Garrison LP, Jr., Neumann PJ, Radensky P, Walcoff SD. A flexible approach to evidentiary standards for comparative effectiveness research. Health Affairs (Millwood) 2010; 29(10):1812-1817.

*Greenberg D, Earle CC, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility studies in oncology. Journal of the National Cancer Institute 2010;102(2):82-88. PubMed: 20056956

*Greenberg D, Rosen AB, Wacht O, Palmer JA, Neumann PJ. A bibliometric review of cost-effectiveness analysis in the economic and medical literature, 1976-2007. Medical Decision Making. Published online March 2010. PubMed: 20228286

Jacobson PD, Neumann PJ. A framework to measure the value of public health services. Health Services Research. In press.

Kozminski MA, Neumann PJ, Nadler ES, Jankovic A, Ubel PA. How long and how well: oncologists’ attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments. Medical Decision Making. 2010. Published online, November 24, 2010.

Lin PJ, Kaufer DI, Maciejewski ML, Ganguly R, Paul JE, Biddle AK. An examination of Alzheimer’s case definitions using Medicare claims and survey data. Alzheimers and Dementia. PubMed: 20434960

Lin PJ, Maciejewski ML, Paul JE, Biddle AK. Risk adjustment for Medicare beneficiaries with Alzheimer’s disease and related dementias. American Journal of Managed Care 2010;16(3):191-198. PubMed: 20225914

Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med. PubMed: 19954941

Luce BR, Drummond M, Jonsson B et al. EBM, HTA, and CER: clearing the confusion. Milbank Q 2010; 88(2):256-276 PubMed: 20579285

McLaughin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan MJ, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Yaakov. Dependence as a unifying contruct in defining Alzheimer’s disease severity. Alzheimer’s and Dimentia 2010; 6(1):482-493.

Meckley LM, Neumann PJ. Personalized medicine: Factors influencing reimbursement. Health Policy 2010;94:91-100. PubMed: 19815307

*Neumann PJ, Auerbach HR, Cohen JT, Greenberg D. “Low-value” services in value-based insurance design. American Journal of Managed Care 2010;16(4):280-286. PubMed: 20394464

Neumann PJ, Drummond MF, Jönsson B, Luce B, Schwartz JS, Siebert U, Sullivan SD. Are key principles for improved health technology assessment supported and used by HTA organizations? International Journal of Technology Assessment in Health Care 2010 Jan;21(1):71-78. PubMed: 20059783

†Neumann PJ, Tunis SR. Medicare and medical technology – the growing demand for relevant outcomes. New England Journal of Medicine 2010;362(5):377-379. PubMed: 20089955

*Neumann PJ, Palmer JA, Fang CH, Nadler E, Ubel PA. Struggling with expensive new cancer therapies: A national survey of oncologists. Health Affairs 2010 Jan;29(1):196-202. PubMed: 20048377

Neumann PJ. American exceptionalism and American health care: Implications for the U.S. debate on cost-effectiveness analysis. Office of Health Economics Briefing. 2009;47. http://www.ohe.org/page/publications/publication.cfm?catid=35&itemid=636&archive=0

Neumann PJ. Are mAbs different? A commentary on Cohen and Wilson. MaBs. 2009;1(1):29-30. http://www.landesbioscience.com/journals/mabs/article/7193/

Neumann PJ. Costing and perspective in published cost-effectiveness analyses. Medical Care. 2009; 47(7s1):s28-s32. Pubmed: 19536023

Neumann PJ. Lessons for health technology assessment: It is not only about the evidence. Value in Health 2009; 12(s2):s45-s48. PubMed: 19523184

Neumann PJ. Whatever happened to FDAMA Section 114? A look back after 10 years. Value Health 2009; 12(2):189-190. PubMed: 18657100

Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity, and methodological improvement. Pharmacoeconomics. In press.

Neumann PJ, Jacobson PD, Palmer JA. Measuring the value of public health systems: The disconnect between health economists and public health practitioners. American Journal of Public Health. 2008 Dec;98(12):2173-2180. PubMed:

Neumann PJ, Kamae MS, Palmer JA. Medicare’s national coverage decisions for technologies, 1999-2007. Health Affairs. 2008 Nov:27(6):1620-1631. PubMed:

Neumann PJ, Weinstein M.C. Legislating against use of cost-effectiveness information. New England Journal of Medecine 2010; 363(16):1495-1497. PubMed

*Otero HJ, Rybicki FJ, Greenberg D, Mitsouras D, Mendoza JA, Neumann PJ. Cost-Effective Diagnostic Cardiovascular Imaging: When Does It Provide Good Value for the Money? International Journal of Cardiovascular Imaging 2010. PubMed:

Otero HJ, Rybicki FJ, Greenberg D, Neumann PJ. 20 years of cost-effectiveness analysis in medical imaging: Are we improving?. Radiology. 2008 Dec;249(3):917-925. PubMed:

Palmer JA, Timm AR, Neumann PJ. Drug Company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999. Journal of Managed Care Pharmacy. 2008;14(8):749-55. PubMed:

Rothberg MB, Cohen JT, Lindenauer P, Maselli J, Auerbach AD. Little Evidence Of Correlation Between Growth In Health Care Spending And Reduced Mortality. Health Affairs (Millwood) 2010; 29(8):1523-1531.

Shaya FT, Yan X, Lin PJ, Simoni-Wastia L, Bron M, Baran R, Donner T. US Trends in Glycemic Control, Treatment, and Comorbidity Burden in Patients With Diabetes. Journal of Clinical Hypertension 2010;12(10):826–832.

 * Publication used data from CEA Registry
 † Publication used data from NCD database